January 2023 decisions news release

The Scottish Medicines Consortium (SMC), which advises on newly-licensed medicines for use by NHSScotland, has today (Monday 16 January) published advice on three new medicines.

The Scottish Medicines Consortium (SMC), which advises on newly-licensed medicines for use by NHSScotland, has today (Monday, January 16) published advice on three new medicines.

Mobocertinib (Exkivity®) was accepted for the treatment of adults with locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy. It was considered through SMC’s Patient and Clinician Engagement (PACE) process, which is used for medicines for end of life and rare conditions.

Tepotinib (Tepmetko®) was accepted for the treatment of adults with advanced non-small cell lung cancer. It was also considered through the PACE process.

The Committee was unable to accept ferric maltol (Feraccru®) as a treatment for iron deficiency as there was uncertainty around its clinical and cost effectiveness.

SMC chairman Mark MacGregor said: “Although the clinical evidence was very limited, mobocertinib and tepotinib may offer further treatment options for non-small cell lung cancer with specific gene mutations. The committee are aware that even small extensions in duration of life are of importance to patients and families.”